Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework

Thrombosis and Thrombocytopenia Syndrome (TTS) has been associated with the AstraZencea (AZ) COVID-19 vaccine (Vaxzevria). Australia has reported low TTS incidence of < 3/100,000 after the first dose, with case fatality rate (CFR) of 5–6%. Risk-benefit analysis of vaccination has been challenging...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Colleen L., Mayfield, Helen J., Sinclair, Jane E., Brown, Samuel J., Waller, Michael, Enjeti, Anoop K., Baird, Andrew, Short, Kirsty R., Mengersen, Kerrie, Litt, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566665/
https://www.ncbi.nlm.nih.gov/pubmed/34810000
http://dx.doi.org/10.1016/j.vaccine.2021.10.079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566665/
https://www.ncbi.nlm.nih.gov/pubmed/34810000
http://dx.doi.org/10.1016/j.vaccine.2021.10.079

Ejemplares similares